Oral selective TYK2 inhibitorGalapagos

GLPG3667

GLPG3667 is an oral, selective TYK2 inhibitor from Galapagos evaluated across interferon-driven autoimmune diseases, including dermatomyositis (GALARISSO) and systemic lupus erythematosus (GALACELA).

Forecast a trial in the Arena Browse all benchmarks

Trials tracked

Resolved

Indications

Targets

GLPG3667 forecasting benchmarks

2 benchmarks

ResolvedPhase 3-enabling

GALARISSO & GALACELA: GLPG3667 (TYK2 inhibitor) in dermatomyositis and SLE

GLPG3667 · Dermatomyositis

Clinical Trials

ResolvedPhase 3-enabling

GALACELA (GLPG3667) Phase 3-enabling study in SLE

GLPG3667 · Systemic lupus erythematosus

Dec 18, 2025Clinical Trials

Mechanism & molecular targets

TYK2· gene

Indications studied

Dermatomyositis· DM Systemic lupus erythematosus· SLE

Developed by

Galapagos· GLPG

About GLPG3667

What is GLPG3667?

GLPG3667 is an oral, selective TYK2 inhibitor from Galapagos evaluated across interferon-driven autoimmune diseases, including dermatomyositis (GALARISSO) and systemic lupus erythematosus (GALACELA). It is a oral selective tyk2 inhibitor developed by Galapagos.

What does GLPG3667 target?

GLPG3667 acts on Tyrosine kinase 2 (TYK2).

How well do AI models predict GLPG3667 trial outcomes?

Open any benchmark below to see the full model leaderboard scored by accuracy, Brier score, and log loss. Models forecast each readout before it is public, so the scores reflect genuine predictive skill rather than hindsight.

References

Keep exploring

All benchmarks Diseases Companies Targets & genes